Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 271-275

  Minami, Seigo ^a   Kijima, Takashi ^b   Hamaguchi, Masanari ^a   Nakatani, Takeshi ^a   Koba, Taro ^a   Takahashi, Ryo ^b   Takeuchi, Yoshiko ^a   Kida, Hiroshi ^b   Nagatomo, Izumi ^b   Yamamoto, Suguru ^a   Tachibana, Isao ^b   Komuta, Kiyoshi ^a   Kawase, Ichiro ^b  

^a OSAKA POLICE HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Epidermal growth factor receptor (EGFR) mutation; Erlotinib; Non squamous non small cell cancer; Pemetrexed; Phase II; Second line chemotherapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOLIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MEDICAL DOCUMENTATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE; VOMITING;

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION; ERLOTINIB; NON-SQUAMOUS NON-SMALL CELL CANCER; PEMETREXED; PHASE II; SECOND-LINE CHEMOTHERAPY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887023339     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.022     Document Type: Article

References (19)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
4. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
5. Giovannetti E., Lemos C., Tekle C., Smid K., Nannizzi S., Rodriguez J.A., et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008, 73:1290-1300.
6. Li T., Ling Y.H., Goldman I.D., Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007, 13:3413-3422.
7. Davies A.M., Ho C., Beckett L., Lau D., Scudder S.A., Lara P.N., et al. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 2009, 4:862-868.
8. Minami S., Kijima T., Takahashi R., Kida H., Nakatani T., Hamaguchi M., et al. Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. BMC Cancer 2012, 12:296.
9. Ranson M., Reck M., Anthoney A., Hanauske A.R., Dean E., Melezinek I., et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol 2010, 21:2233-2239.
10. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212.
11. Maruyama R., Nishiwaki Y., Tamura T., Yamamoto N., Tsuboi M., Nakagawa K., et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008, 26:4244-4252.
12. Pawel J., Papai-Szekely Z., Vinolas N., Sederholm C., Klima M., Desaiah D., et al. A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC. J Clin Oncol 2011, 29:abstr7526.
13. Aerts J.G., Codrington H., Burgers S., Biesma B., Dalesio O., Dingemans A.-M.C., et al. A randomized phase II study comparing erlotinib (E) versus E alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 study. Ann Oncol 2012, LBA29.
14. Lee D.H., Lee J.S., Kim S.W., Rodrigues Pereira J., Han B., Song X.Q., et al. A randomized phase 2 study of erlotinib plus pemetrexed vs erlotinib or pemetrexed alone as second-line treatment for never-smoker patients with non-squamous advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012, 23. Oral Presentation 1225.
15. Yoshioka H., Hotta K., Kiura K., Takigawa N., Hayashi H., Harita S., et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 2010, 5:99-104.
16. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
17. Kubota K., Niho S., Enatsu S., Nambu Y., Nishiwaki Y., Saijo N., et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 2009, 4:1530-1536.
18. Kubota K., Nishiwaki Y., Tamura T., Nakagawa K., Matsui K., Watanabe K., et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008, 3:1439-1445.
19. Takahashi T., Yamamoto N., Nukiwa T., Mori K., Tsuboi M., Horai T., et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010, 30:557-563.